Veranex Acquires Leading Preclinical Services Provider T3 Labs

Recently Veranex acquired T3 Labs, a state-of-the-art, highly reputable preclinical laboratory located in Atlanta, Georgia. This acquisition solidifies our commitment to expanding our preclinical footprint in North America, supporting the increasing regulatory demands and enabling more efficient collaboration with clients in their product development.

While our Paris lab is already well-known as a preeminent leader within the cardiovascular space, the addition of our North American facility brings a broader array of cardiovascular and non-cardiovascular expertise into our portfolio of offerings. We’ve expanded our capabilities to encompass 12 total therapeutic areas including orthopedic, GI/urology, and more as well as offering bioskills training. The staff at T3 Labs brings deep preclinical medical device expertise to our existing team, having contributed to more than 60 products being approved by the FDA over the past 10 years.

StandTogether | Georgia Life Sciences Institute - EPIC

January 14, 2026
What happens when students see real work before choosing a future 

America's Biotech Leadership Depends on the States

By Maria Thacker Goethe • January 8, 2026
By: Patrick Plues | RealClearHealth January 8, 2026 For decades, America has led the global biotech industry – thanks, in part, to state-level policies that encourage research and manufacturing investments. But other countries, including China, are sparing no expense in the bid to overtake us. Beijing has officially made biotechnology a national strategic priority and is pouring billions into state-backed research and manufacturing efforts. All states should consider impactful biotech policies that grow and strengthen our domestic biotechnology industry. If states fail to utilize and replicate what are considered to be the best and most successful policies in biotech-focused economic development, the United States will soon lose its long-term leadership in developing medicines and medical technologies, which underpin our health, our economy, and our national security. Thankfully, many governors and state legislatures around the country are already answering this call -- as our new study, The U.S. Bioscience Industry: A Powerful Engine for State Economies, demonstrates. Keep Reading at https://www.realclearhealth.com/2026/01/08/americas_biotech_leadership_depends_on_the_states_1157584.html

GLS 2025 Year in Review

December 22, 2025
Dear Georgia Life Sciences Community, As we reflect on the past year, I want to extend my sincere thanks to our Georgia Life Sciences members for making it such an impactful one. Your engagement and leadership continue to move our industry forward and advance our shared strategic priorities— driving strong policy, expanding the talent pipeline, and creating intentional spaces for collaboration across Georgia’s life sciences ecosystem. Our Year in Review captures the progress we’ve made together across these priorities and highlights the collective impact our members are having statewide—from strengthening the workforce and supporting manufacturing growth to elevating Georgia’s position as a national life sciences leader. This progress is only possible because of the collaboration, commitment, and insight of our member community. 
MORE POSTS